Overview
TellBio, Inc. is a development-stage biotechnology company based in Beverly, Massachusetts. The company is committed to revolutionizing cancer detection and treatment, emphasizing the liberation of patients from cancer. At the core of TellBio's innovation is the TellDx CTC System, a proprietary circulating tumor cells (CTCs) technology platform. This system is significant for its ability to detect and monitor cancer progression. TellBio's technology is utilized worldwide at leading centers of excellence as a research tool in cancer diagnostics.
Leadership and Team
Richard Peters, MD, PhD
Dr. Richard Peters, the Founder and Executive Chairman of TellBio, brings over three decades of experience in healthcare and academia. He has held multiple leadership roles, such as Global Head of Sanofi Genzyme’s Rare Diseases business and CEO of both Yumanity Therapeutics and Merrimack Pharmaceuticals. An alumnus of Massachusetts General Hospital and Harvard Medical School, Dr. Peters holds advisory and chair roles at prominent biopharmaceutical firms.
Annie Partisano, PharmD, MS
Annie Partisano is the Senior Vice President and Head of Operations at TellBio. With more than 15 years in the pharmaceutical industry, she has significantly contributed to companies like Kiniksa Pharmaceuticals and Alnylam Pharmaceuticals, especially in medical affairs strategies. She holds a Doctor of Pharmacy and a Master of Science in Regulatory Affairs from Northeastern University and has been recognized by the Healthcare Businesswomen’s Association.
Technology and Innovation
TellBio's TellDx CTC System employs microfluidic diagnostic tools to detect viable circulating tumor cells, agnostic to the primary solid tumor’s origin. This technology, licensed exclusively from Massachusetts General Hospital, is derived from intensive academic and clinical research, representing a potentially transformative innovation in cancer diagnostics.
Recent News and Developments
TellBio has demonstrated significant translational and clinical applications of its platform, particularly for prostate and breast cancer. Their advancements indicate promising results in predicting patient survival undergoing specific cancer treatments.
Financial Standing and Funding
TellBio has secured a total of $10.7 million through multiple funding rounds. The company raised approximately $4.9 million in a Series A funding round in March 2021 and added $2.2 million in March 2023. Investment partners include Crocker Ventures, ARUP Laboratories, National Foundation for Cancer Research, Genetron Health, and AIM-HI.
Partnerships and Collaborations
TellBio’s strategic partnerships with academic, clinical, and research organizations are pivotal, as these alliances are instrumental in utilizing and exploring the TellDx CTC System to enhance its presence in the market.
Competitor Profiling
Main Competitors
TellBio operates in a competitive biotechnology landscape, with key competitors such as:
1. Amgen Inc.: A pioneering biotechnology firm concentrating on treatments for cancer, heart disease, and inflammatory conditions.
2. AstraZeneca: Specializes in oncology and biopharmaceutical advancements, with a significant focus on sustainable healthcare.
3. CureVac: Innovators in mRNA technology, emphasizing mRNA-based therapies for personalized medicine and oncology.
4. OncoSil Medical: Known for localized cancer treatments employing interventional oncology techniques.
5. TheraBionic Inc.: Developers of the TheraBionic P1 device, which uses tumor-specific radio frequencies for treating cancers like hepatocellular carcinoma.
6. EMulate Therapeutics: Focuses on therapeutic devices in neurology and oncology sectors.
Competitive Landscape Analysis
Innovation and Technological Edge
- Amgen and AstraZeneca lead with diverse R&D pipelines, utilizing AI and generative biology for product innovation.
- CureVac distinguishes itself through its mRNA technology for groundbreaking cancer and disease treatments.
- TheraBionic offers a non-invasive, side-effect-free cancer therapy solution with its P1 device.
Market Strategy and Presence
- Amgen operates globally in nearly 100 countries, driving growth through R&D investments and strategic acquisitions.
- AstraZeneca’s sustainability-driven approach and organizational reach bolster its pharmaceutical delivery worldwide.
- OncoSil Medical and TheraBionic concentrate on niche markets, providing specialized oncology solutions.
Financial Performance and Growth
Amgen and AstraZeneca exhibit financial robustness with the introduction of first-in-class therapies. Meanwhile, TellBio, with its developing funding trajectory, is positioned to advance its technology supported by its stakeholders.
TellBio’s emphasis on innovation and proprietary technologies like TellDx underscores its competitive stance in cancer treatment. Ongoing strategic partnerships and investments reinforce its footprint in this dynamic sector.
